RespireRx Pharmaceuticals Inc (fka RSPI)

[neuroinv]

1) Ms. Messinger does not execute the CFO duties that most of her peers do--she plays no part in fundraising that I can discern. I posted a couple weeks ago that Cortex should consider hiring a real CFO--who can lead the fundraising efforts. Messinger appears to run company finances--but that is different from developing and utilizing financing sources.
2) All negotiations are done under a CDA--confidentiality agreement. Cortex cannot tell other people; Merck offered us $41 million, beat that. But I expect there will be more than one company that will say--call us before you accept any other bid. They could call Lilly, whose bid is at $38 million upfront, and say--we have an offer we are going to accept--unless you can come up $4 million from your previous bid. That does not violate the CDA.
3) <<If Stoll were to decide to step down on Monday and a new qualified CEO was named, I would guess that this stock would be back over $2.00.>> Really? I guess we'll never know, but I think the stock would be at 1.25.

NeuroInvestment